公开(公告)号：US20240309080A1

公开(公告)日：2024-09-19

申请号：US18277608

申请日：2022-03-02

申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.

发明人： Lingjie KONG ,  Yanju CHENG ,  Xiaolu GUO

IPC分类号： C07K16/24 ,  A61K39/00 ,  A61K47/02 ,  A61K47/06 ,  A61K47/26

CPC分类号： C07K16/244 ,  A61K47/02 ,  A61K47/06 ,  A61K47/26 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/565

摘要： Provided are a pharmaceutical composition containing an anti-TSLP antibody, and a use thereof. In particular, provided are a pharmaceutical composition, containing (a) an anti-TSLP antibody, (b) a buffer, (c) a surfactant, and one or more (d) stabilizers, and a use of the pharmaceutical composition in preparation of a medicament for treating and preventing TSLP-related diseases.

公开(公告)号：US20220289825A1

公开(公告)日：2022-09-15

申请号：US17637697

申请日：2020-08-28

申请人： Nanjing Shunxin Pharmaceuticals Co., Ltd., Of Chiatai Tianqing Pharmaceutical Group ,  Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

发明人： Wei ZHAO ,  Yingchun LI ,  Lianxiang XIE ,  Yamin LU ,  Haili LV ,  Xiuzhen DU ,  Tongjie XU ,  Yanju CHENG ,  Xiquan ZHANG

IPC分类号： C07K14/71 ,  A61P35/00 ,  C12N15/63 ,  C07K14/705

摘要： Provided are a fusion protein targeting PD-L1 and TGF-β and use thereof. The fusion protein is a fusion protein comprising an antibody or antigen-binding fragment that specifically binds to human PD-L1 and a human TGFβRII binding domain. Further provided are a polynucleotide encoding the fusion protein, a host cell containing the polynucleotide, and the use of the fusion protein in the preparation of an anti-tumor drug.

公开(公告)号：US20240343815A1

公开(公告)日：2024-10-17

申请号：US18293838

申请日：2022-08-25

申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.

发明人： Yanju CHENG ,  Yingchun LI ,  Lingjie KONG ,  Xiaolu GUO ,  Wei ZHAO

IPC分类号： C07K16/28 ,  A61K9/19

CPC分类号： C07K16/2866 ,  A61K9/19 ,  C07K2317/24 ,  C07K2317/565

摘要： A pharmaceutical composition of an anti-IL4R antibody and a use thereof, wherein the pharmaceutical composition includes the anti-IL4R antibody or an antigen binding fragment thereof, and a buffering agent; and the pharmaceutical composition can further include a surfactant and a stabilizer.

公开(公告)号：US20230279138A1

公开(公告)日：2023-09-07

申请号：US18007012

申请日：2021-07-26

申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.

发明人： YOUWEI ZHU ,  Yingchun LI ,  Yanju CHENG

IPC分类号： C07K16/28 ,  A61K47/12 ,  A61K47/22 ,  A61K9/19

CPC分类号： C07K16/2887 ,  C07K16/2809 ,  A61K47/12 ,  A61K47/22 ,  A61K9/19 ,  A61K2039/505

摘要： The present invention provides a novel bispecific anti-CD3/CD20 polypeptide complex formulation containing a first antigen-binding portion and a second antigen-binding portion. Specifically, the formulation comprises a liquid formulation and a lyophilized formulation.

公开(公告)号：US20200237906A1

公开(公告)日：2020-07-30

申请号：US16756409

申请日：2018-11-02

申请人： NANJING SHUNXIN PHARMACEUTICAL CO., LTD. ,  CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD

发明人： Jianwen LI ,  Yanju CHENG ,  Yingchun LI ,  Wei ZHAO ,  Xiquan ZHANG

IPC分类号： A61K39/395 ,  A61K47/26 ,  A61K47/02 ,  A61K47/10 ,  A61K47/14

摘要： The invention is in the field of antibody formulations, and particularly relates to a pharmaceutical composition of a humanized monoclonal anti-PD-L1 antibody, wherein the pharmaceutical composition comprises 1-150 mg/ml of the humanized monoclonal anti-PD-L1 antibody, a buffer at 3-50 mM, 2-150 mg/ml of an isotonic adjuster/stabilizer and 0.01-0.8 mg/ml of a surfactant, and has a pH of about 4.5-6.8. The formulations prevent antibody aggregates therein from increasing, while enabling better maintenance of the biological binding activity of the antibody for a long time.